A Molecular Genetic Registry as a Tool for Personalized Treatment of Non-small Cell Lung Cancer

Background: Given the rising incidence of cancer, particularly lung cancer, along with advancements in molecular genetic research, there is an increasing need to implement modern diagnostic approaches based on the assessment of molecular alterations. The study of molecular genetic changes in lung cancer is a critical step toward the timely initiation of targeted therapies and the prediction of disease progression. The establishment of molecular genetic study registry will enable the systematic collection and analysis of data on the genomics of non-small cell lung cancer (NSCLC), tumor histology, disease stages, and treatment strategies. Furthermore, such a registry will enhance accurate epidemiological analyses and, in the future, support the identification of cancer distribution patterns as well as monitoring of treatment outcomes.
Objective: Сreation of a registry for molecular-genetic data for personalized treatment of lung cancer.
Materials and methods: An analysis of 128 clinical cases diagnosed with NSCLC was conducted using Next–Generation Sequencing (NGS) on the MiSeqDX platform (Illumina, USA) in accordance with the manufacturer’s instructions.
Results: In the course of the study, the obtained results, including genetic data, were systematically organized in a registry, on the basis of which both population characteristics and individual patient data were generated. The most frequently identified mutations were in the KRAS and EGFR genes: 28% and 19%, respectively. Some patients were found to have rare mutations in ALK (2%), BRAF (1%), RET (2%), which may require specific targeted therapies. Among the 128 patients, 49 cases of various co-mutations were identified, which may affect treatment resistance and disease progression.
Сonclusion: The implementation of a molecular genetic research registry has enabled a comprehensive analysis of population characteristics and personalized treatment strategies for individual patients.

1. Murashko R., Shmatkova A. Dynamics of oncological morbidity of the population of the Krasnodar Territory. Voprosy Onkologii. 2021;67(5):630–634. (In Russ.). https://doi.org/10.37469/0507-3758-2021-67-5-630-634

2. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. PMID: 34273294 https:// doi.org/10.1016/s0140-6736(21)00312-3

3. Kaprin AD, Chissov VI, Starinsky VV, et al. The information analytical system for registration of cancer patients in the Russian Federation. Onkologiya. Zhurnal imeni P.A.Gertsena. 2015;4(5):40‑43. (In Russ.) https://doi.org/10.17116/onkolog20154540-43

4. Gebremariam TH, Haisch DA, Fernandes H, et al. Clinical Characteristics and Molecular Profiles of Lung Cancer in Ethiopia. JTO Clin Res Rep. 2021;2(7):100196. PMID: 34590041. PMCID: PMC8474241. https://doi.org/10.1016/j.jtocrr.2021.100196

5. Mausey N, Halford Z. Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib. Ann Pharmacother. 2024;58(6):622-635. PMID: 37700573. https://doi.org/10.1177/10600280231197459

6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. PMID: 29455650. PMCID: PMC5817870. https://doi.org/10.1186/s12943-018-0777-1

7. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. PMID: 29151359. https://doi.org/10.1056/nejmoa1713137

8. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23-e31. PMID: 21764376. https://doi.org/10.1016/s1470-2045(11)70129-2

9. Liu S, Lowder KE. Mobocertinib in non-small cell lung cancer. Drugs Today (Barc). 2022;58(11):523-530. PMID: 36422513. https://doi.org/10.1358/dot.2022.58.11.3408816

10. Brazel D, Nagasaka M. The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023;24(1):256. PMID: 37880647. PMCID: PMC10601226. https://doi.org/10.1186/s12931-023-02558-4

11. Wang R, Pan S, Song X. Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer. ZhongguoFei Ai Za Zhi. 2022;25(3):174-182. PMID: 35340160. PMCID: PMC8976205. https://doi.org/10.3779/j.issn.1009-3419.2022.101.06

12. Canale M, Petracci E, Delmonte A, et al. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non- Small Cell Lung Cancer Patients Treated with TKIs. J Clin Med. 2020;9(4):1047. PMID: 32272775. PMCID: PMC7230306. https:// doi.org/10.3390/jcm9041047

13. Proulx-Rocray F, Routy B, Nassabein R, et al. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treat Res Commun. 2023;37:100767. PMID: 37832364. https://doi.org/10.1016/j.ctarc.2023.100767

14. Aredo JV, Padda SK, Kunder CA, et al. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer. 2019;133:144-150. PMID: 31200821. PMCID: PMC9348589. https://doi.org/10.1016/j.lungcan.2019.05.015

15. Budczies J, Romanovsky E, Kirchner M, et al. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Br J Cancer. 2024;131(3):524-533. PMID: 38866964. PMCID: PMC11300455. https://doi.org/10.1038/s41416-024-02746-z

16. Bange E, Marmarelis ME, Hwang WT, et al. Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019;3:PO.18.00326. PMID: 31428721. PMCID: PMC6699781. https://doi.org/10.1200/po.18.00326